Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. RESEARCH DESIGN AND METHODS: In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks’ open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change between randomized groups. RESULTS: Of 821 participants completing the run-in, 61% (n = 498) achieved A1C <7% (mean change −1.3% from 7.7% at start), whereas 39% (n = 323) did not (−0.6% from 8.3% at start). During run-in, 167 of 988 (17%) withdrew; 46% of these due to gastrointestinal adverse events. At week 26, A1C decreased further, by 0.5% (from 7.6% at randomization) with insulin detemir (n = 162) versus 0.02% increase without insulin detemir (n = 157) to 7.1 and 7.5%, respectively (estimated treatment difference −0.52 [95% CI −0.68 to −0.36]; P < 0.0001). Forty-three percent of participants with insulin detemir versus 17% without reached A1C <7%. Mean weight decreased by 3.5 kg during run-in, then by 0.16 kg with insulin detemir or 0.95 kg without insulin detemir. In the randomized phase, no major hypoglycemia occurred and minor hypoglycemia rates were 0.286 and 0.029 events per participant-year with and without insulin detemir (9.2 vs. 1.3%). CONCLUSIONS: Supplementation of metformin with liraglutide and then insulin detemir was well tolerated in the majority of patients, with good glycemic control, sustained weight loss, and very low hypoglycemia rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Use of the amylin analog pramlintide in conjunction with bolus insulin improves both glycemia and weight in persons with T2D.1092,1093”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1092]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“greater glycemic efficacy and weight loss (6), they may be more beneficial than these oral agents after metformin, but less acceptable in some patients because of gastrointestinal side effects and the injection barrier.”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationInternational Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · cited 1×
“The higher dose may have favored efficacy outcomes and weight loss but adversely affected tolerability (11,24).”
Backgroundon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Research works printed but not linked: 1
- Samarasinghe, 2008, The short term effects of exenatide therapy in insulin treated patients with type 2 diabetes mellitus–a new option to achieve weight loss (Abstract), Diabetologia, 51, S353
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
“Although adding a GLP-1 receptor agonist as the third agent may successfully lower glycemia, eventually many patients will still require insulin (121,122).”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
“Although adding a GLP-1 receptor agonist as the third agent may successfully lower glycemia, eventually many patients will still require insulin (126,127).”
BackgroundEng, C., Kramer, C. K., Zinman, B., & Retnakaran, R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61335-0 · Cited by 383
Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V. (2014) · Diabetes Care · doi:10.2337/dc13-2759 · Cited by 341
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“Although adding a GLP1 receptor agonist as the third agent may successfully lower glycemia, eventually many patients will still require insulin (243,244).”
BackgroundRiddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288
“Recently, a 26-week randomized study of combining liraglutide with basal insulin has been reported (28), in which the inverse order of the introduction of drugs was tested.”
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Timothy Garvey, W., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.cs · Cited by 280
Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268
Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care · doi:10.2337/dc14-0785 · Cited by 259
Self-citationGlucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
Blonde, L., Jendle, J., Gross, J., Woo, V., Jiang, H., Fahrbach, J. L., & Milicevic, Z. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60936-9 · Cited by 227
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 220
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
“GLP-1 analogues are often used in combination with insulin products, and liraglutide in combination with insulin detemir and insulin degludec has been shown to provide good glycaemic control, sustained weight loss and low rates of hypoglycaemia [16, 55].”
BackgroundRosenstock, J., Fonseca, V. A., Gross, J. L., Ratner, R. E., Ahrén, B., Chow, F. C. C., Yang, F., Miller, D., Johnson, S. L., Stewart, M. W., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0001 · Cited by 211
Self-citationPotts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126769 · Cited by 163
“9 Pharmaceutical DeVries (2011) [44] Insulin Detemir + Liraglutide 1.”
BackgroundMathieu, C., Rodbard, H. W., Cariou, B., Handelsman, Y., Philis‐Tsimikas, A., Ocampo Francisco, A. M., Rana, A., Zinman, B., & on behalf of the BEGIN: VICTOZA ADD‐ON (NN1250‐3948) study group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12262 · Cited by 158
Self-citationJendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Ahren, B. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33934 · Cited by 148
Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0157-z · Cited by 135
“T2DM Basal-Oral Therapy Seven RWD studies [32–38] and 10 RCTs [23, 39–47] reported hypoglycemia event rates in people with insulin-treated T2DM receiving basal-oral regimens (Table 2; Supplementary Table II).”
BackgroundBalena, R., Hensley, I. E., Miller, S., & Barnett, A. H. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12025 · Cited by 142
“Nausea was most common, affecting 23–41% of exenatide BID-treated patients [41,49,52], 40% of lixisenatide QD-treated patients [53], and 17–26% of liraglutide-treated patients [57].”
BackgroundInfluentialLinjawi, S., Bode, B. W., Chaykin, L. B., Courrèges, J.-P., Handelsman, Y., Lehmann, L. M., Mishra, A., & Simpson, R. W. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0218-3 · Cited by 136
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 150
Maiorino, M. I., Chiodini, P., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2017) · Diabetes Care · doi:10.2337/dc16-1957 · Cited by 125
“Four trials (12,13,15,20) tested the superiority of the combination (GLP-1RA and in-”
BackgroundRodbard, H. W., Bode, B. W., Harris, S. B., Rose, L., Lehmann, L., Jarlov, H., Thurman, J., & the Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators (2017) · Diabetic Medicine · doi:10.1111/dme.13256 · Cited by 109
Self-citationAhmann, A., Rodbard, H. W., Rosenstock, J., Lahtela, J. T., de Loredo, L., Tornøe, K., Boopalan, A., Nauck, M. A., & on behalf of the NN2211‐3917 Study Group (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12539 · Cited by 104
“Elevations in lipase and amylase after week 26 were similar to those reported previously [21,31,46,47].”
BackgroundMethodResultInfluentialSelf-citationDungan, K. M., Weitgasser, R., Perez Manghi, F., Pintilei, E., Fahrbach, J. L., Jiang, H. H., Shell, J., & Robertson, K. E. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12634 · Cited by 99
“Consistent with the class, measurable increases in pancreatic enzymes were observed, but there were no adjudicated cases of pancreatitis and no cases of pancreatic carcinoma [18,27,29,30].”
Lane, W., Weinrib, S., Rappaport, J., & Hale, C. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12286 · Cited by 91
Steinberg, W. M., Nauck, M. A., Zinman, B., Daniels, G. H., Bergenstal, R. M., Mann, J. F. E., Steen Ravn, L., Moses, A. C., Stockner, M., Baeres, F. M. M., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000229 · Cited by 79
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Hanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 71
Self-citationCombining GLP ‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
Holst, J. J., & Vilsbøll, T. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01628.x · Cited by 63
“1 episodes/patient/year for ILPS and GLAR, respectively) [95] DET added to LIRA (N = 162) LIRA (N = 161) Metformin 26 weeks Baseline HbA1c (following study run-in): 7.”
MethodHarris, K. B., & McCarty, D. J. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814558242 · Cited by 57
Seino, Y., Kaneko, S., Fukuda, S., Osonoi, T., Shiraiwa, T., Nishijima, K., Bosch‐Traberg, H., & Kaku, K. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12457 · Cited by 58
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Mondal, S., Samajdar, R. N., Mukherjee, S., Bhattacharyya, A. J., & Bagchi, B. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b11928 · Cited by 58
“We can define two types of time correlation functions using these definitions namely continuous hydrogen bond correlation, SHB(t) and intermittent hydrogen bond correlation, CHB(t) as defined in Eq (3).”
MethodGLP-1R agonist therapy for diabetes: benefits and potential risks
Samson, S. L., & Garber, A. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835edb32 · Cited by 55
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55
Benefits of timely basal insulin control in patients with type 2 diabetes
Lovre, D., & Fonseca, V. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.11.018 · Cited by 60
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
Ahrén, B. (2014) · World J Diabetes · doi:10.4239/wjd.v5.i1.40 · Cited by 51
Rosenstock, J., Rodbard, H. W., Bain, S. C., D’Alessio, D., Seufert, J., Thomsen, A. B., Svendsen, C. B., & DeVries, J. H. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.008 · Cited by 46
“Wepreviously published the results observed 26 weeks after randomization (DeVries et al., 2012).”
BackgroundMethodResultInfluentialSelf-citationInsulin Detemir: A Review of its Use in the Management of Diabetes Mellitus
Keating, G. M. (2012) · Drugs · doi:10.2165/11470200-000000000-00000 · Cited by 56
Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0321-6 · Cited by 47
“05) [30] or add-on insulin degludec (-1.”
BackgroundMethodInfluentialCombining Incretin-Based Therapies With Insulin
Vora, J. P. (2013) · Diabetes Care · doi:10.2337/dcs13-2036 · Cited by 45
Hinnen, D. (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.4.175 · Cited by 42
“However, one recent study (50) evaluated a treatment intensification sequence of adding a GLP-1 receptor agonist to metformin, followed by further intensification with systematically titrated basal insulin in patients with an A1C level ≥7%.”
BackgroundFocus on therapeutic peptides and their delivery
Rosson, E., Lux, F., David, L., Godfrin, Y., Tillement, O., & Thomas, E. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125555 · Cited by 39
New Developments in Diabetes Management: Medications of the 21st Century
Fonseca, V. A. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.01.018 · Cited by 38
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
Gough, S. C. L., Jain, R., & Woo, V. C. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1113129 · Cited by 40
Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis
Lee, C. M. Y., Woodward, M., & Colagiuri, S. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.037 · Cited by 37
Chitnis, A. S., Ganz, M. L., Benjamin, N., Langer, J., & Hammer, M. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0153-5 · Cited by 37
“The liraglutide effect and action in diabetes (LEAD) pivotal clinical trials and the 1860 liraglutide dipeptidyl peptidase-4 inhibitor (LIRA-DPP-4) study have analyzed liraglutide against various active comparators across the treatment cascade [4–11].”
BackgroundIntensifying Insulin Therapy: What Options Are Available to Patients with Type 2 Diabetes?
Meneghini, L. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.011 · Cited by 38
Maiorino, M. I., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., & Esposito, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.06.009 · Cited by 36
Aroda, V. R., Bailey, T. S., Cariou, B., Kumar, S., Leiter, L. A., Raskin, P., Zacho, J., Andersen, T. H., & Philis‐Tsimikas, A. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12661 · Cited by 33
“GLP-1 RAs and basal insulin address different but complementary physiological approaches to treating hyperglycaemia.”
ResultInfluentialComplementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 38
“5% [104].”
Blonde, L., Anderson, J. E., Chava, P., & Dendy, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541790 · Cited by 33
Cimmaruta, D., Maiorino, M., Scavone, C., Sportiello, L., Rossi, F., Giugliano, D., Esposito, K., & Capuano, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221402 · Cited by 33
“[27–36], whereas the opposite (insulin added to an existing GLP-1 RA regimen) occurred in 2 studies [37,38].”
BackgroundMethodVora, J. P., Bain, S. C., Damcı, T., Dzida, G. J., Hollander, P. A., Meneghini, L., & Ross, S. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.002 · Cited by 34
Self-citationComposite endpoints in trials of type‐2 diabetes
Einarson, T. R., Garg, M., Kaur, V., & Hemels, M. E. H. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12226 · Cited by 30
The role of FGF21 in type 1 diabetes and its complications
Zhang, J., Weng, W., Wang, K., Lu, X., Cai, L., & Sun, J. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.25026 · Cited by 32
“However, sometimes, insulin therapy have suboptimal effects on glycemic control, many side effects can be observed [2, 3].”
BackgroundCombining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations
Carris, N. W., Taylor, J. R., & Gums, J. G. (2014) · Drugs · doi:10.1007/s40265-014-0325-2 · Cited by 28
“(ii) This treatment strategy has a low risk for hypoglycemia [20].”
BackgroundInfluentialMeier, J. J., Menge, B. A., Schenker, N., Erdmann, S., Kahle‐Stephan, M., Schliess, F., Kapitza, C., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13935 · Cited by 24
Abdi, H., Azizi, F., & Amouzegar, A. (2018) · Intern J Endocrinol Metab · doi:10.5812/ijem.65600 · Cited by 24
“ticipants (76-90) assessing different outcomes of basal insulin-GLP-1 agonist combination therapy compared to other hypoglycemic agents (91) demonstrated that combined treatment results the followings: 1) greater reduc-”
BackgroundResultInfluentialRados, D. R. V., Falcetta, M. R. R., Pinto, L. C. F., Leitão, C. B., & Gross, J. L. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108688 · Cited by 25
Umpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 25
Porcellati, F., Lucidi, P., Bolli, G. B., & Fanelli, C. G. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30004-0 · Cited by 22
Harris, S. B., Abrahamson, M. J., Ceriello, A., Charpentier, G., Evans, M., Lehmann, R., Liebl, A., Linjawi, S., Holt, R. I. G., Hosszúfalusi, N., et al. (2020) · Drugs · doi:10.1007/s40265-019-01245-3 · Cited by 22
Importance of achieving the composite endpoints in diabetes
Unnikrishnan, A., Bhattacharyya, A., Baruah, M., Sinha, B., Dharmalingam, M., & Rao, P. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.117225 · Cited by 20
“[21] Thus; this case demonstrates the importance of CEP in assessing the net clinical bene fi t of an intervention.”
InfluentialNadeau, D. A. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2666 · Cited by 18
Andersen, B., Omar, B. A., Rakipovski, G., Raun, K., & Åhrén, B. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.07.003 · Cited by 21
“However, despite the effectiveness of insulin therapy, some individuals still have difficulty maintaining good glycemic control (DeVries et al., 2012).”
BackgroundIDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes
Hughes, E. (2016) · Primary care diabetes · doi:10.1016/j.pcd.2015.12.005 · Cited by 18
Mulligan, C., Harper, R., Harding, J., McIlwaine, W. J., Petruckevitch, A., & McLaughlin, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0025-z · Cited by 17
Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review
Goldenberg, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.852078 · Cited by 18
Injectable Coformulations in Diabetology
Kalra, S., & Gupta, Y. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0106-2 · Cited by 17
GLP-1 receptor agonists in the treatment of Type 2 diabetes
Bo, A.-R. (2013) · Diabetes Management · doi:10.2217/dmt.13.41 · Cited by 31
Scholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 18
“5 % HbA1c), induction of a further slight weight loss after randomization, and no severe hypoglycemic events as well as very low rates of minor hypoglycemia and other side effects [DeVries et al. 2012].”
BackgroundMethodDefining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16
Lixisenatide as add-on therapy to basal insulin
Evans, M., Butler, E. L., & Brown, D. X. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45108 · Cited by 17
Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy
Kumar, A. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.904851 · Cited by 17
Jung, H. N., Cho, Y. K., Min, S. H., Kim, H. S., Kim, Y., Park, J., Lee, W. J., & Jung, C. H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.870722 · Cited by 17
“had a run-in period before randomization and withdrew all OADs excluding metformin at the start of the runin phase (16, 17).”
MethodInfluentialIncorporating Incretin-Based Therapies into Clinical Practice for Patients with Type 2 Diabetes
Tibaldi, J. M. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0100-5 · Cited by 14
“When used in combination with GLP-1RAs or DPP-4 inhibitors, exogenous insulin is augmented with endogenous, glucose-dependent insulin secretion, allowing the body to compensate for increased carbohydrate intake without increasing the dose of exogenous insulin and, consequently, risk of hypoglycemia [28, 31–33].”
BackgroundMethodUmpierrez, G. E., & Meneghini, L. (2013) · Endocrine Practice · doi:10.4158/ep12292.ra · Cited by 12
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
“2 mg/dL) compared with continued metformin plus liraglutide [103].”
BackgroundVilsbøll, T., Vora, J. P., Jarlov, H., Kvist, K., & Blonde, L. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0376-0 · Cited by 12
“Many clinical studies have demonstrated such clinical benefits with this regimen [11–22], and the tolerability of this combination relative to intensified insulin therapy is especially appealing and may benefit treatment adherence.”
BackgroundArakaki, R. F., Blevins, T., Wise, J. K., Liljenquist, D. R., Jiang, H. H., Jacobson, J. G., Martin, S., & Jackson, J. A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12242 · Cited by 13
“Adding basal insulin to regimens containing GLP-1 RAs has been noted to be more logical than the converse order (GLP-1 RA added to basal insulin) when progressive antihyperglycaemic therapy in T2D is required [10].”
BackgroundRoss, S. A. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.973939 · Cited by 12
“8 mg 68 35% SITA 100 mg 219 6% DeVries et al.(73) HbA1c57þ NWGþ NH 26 weeks LIRA-1.”
Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
Vidal, J. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.02.76 · Cited by 15
Rosenstock, J., BAJAJ, H. S., Lingvay, I., & Heller, S. R. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003930 · Cited by 12
Self-citationLisco, G., Tullio, A. D., Guastamacchia, E., & Triggiani, V. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200705211224 · Cited by 13
The future of insulin therapy for patients with type 2 diabetes mellitus.
Tibaldi, J. M. (2013) · PubMed · Cited by 14
Metadata
- Authors
- DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Swansea University (GB)
- Endocrine and Metabolic Associates, Rockville, Maryland
- University Medical Center Freiburg (DE)
- Cincinnati VA Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- Medical City Dallas Hospital (US)
- Corresponding author
- Rosenstock, Julio
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-06-12
- Volume
- 35
- Issue
- 7
- Pages
- 1446-1454
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3379583
- OpenAlex
- W2160274347
- Cited by
- 159
- References
- 27
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 5 · 2019: 5 · 2018: 9 · 2017: 6 · 2016: 18 · 2015: 25 · 2014: 27 · 2013: 33 · 2012: 13
- FWCI
- 25.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion)
- Funders
- American Diabetes Association
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Intarcia Therapeutics
- MannKind Corporation
- MacroGenics
- Diabetes UK
- Novo Nordisk
- Servier
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, metformin, liraglutide, insulin detemir, weight loss, hypoglycemia, gastrointestinal adverse effects, GLP-1 receptor agonists, glycemic control
- MeSH terms
- Insulin Detemir, Liraglutide, Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Insulin, Long-Acting, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.